New paper! [A 🧵 1/6]
APP and HDAT compared to antipsychotic monotherapy at standard doses in schizophrenia – a systematic review - Christopher Lawrence, Chloe Roberts, Chloe Galides, Samuel R Chamberlain, Ruihua Hou, 2024 https://t.co/WZXqFPMKE6
Clozapine does not work for everyone, but if we are going to continue trying APP and HDAT, we need some more high-quality large-scale RCTs to find what works [end 🧵6/6]
We found very little evidence for the efficacy of APP and HDAT in the treatment of schizophrenia over the use of antipsychotic monotherapy at a standard dose. 2/6
@dr_l_evans I agree, I like to always explain WHY I’ve made a decision rather than just stating the concluding plan. Can’t say anyone has ever praised me for it though 😂
Going to be a moment in the second half where Harry Kane falls over and either 1. scores the pen to win the tournament and get the golden boot or 2. is sent off
This is not a general point
For years, the narrative around mental healthcare has ignored a group with psychotic illness who do not engage with services and who, when unwell, have high risks
They need targeted support
They need Assertive Outreach https://t.co/NE6MeoRsPC
New paper out in Journal of Psychopharmacology
BNF maximum doses for psychosis drugs based on safety, not efficacy. Not for use as guideline / target to achieve clinical response. Point of futility often much lower @DrSamMcLean @adamjameson96 @ChrisL8888
https://t.co/HecyriWfpT